Bladder cancer: Pioglitazone-when is a prescription drug safe?

Research output: Contribution to journalAbstractpeer-review

2 Citations (Scopus)


In a recent issue of JAMA, Lewis et al. present long-term data on the likelihood of a link between pioglitazone and the risk of bladder cancer and ten other cancers. Their findings contradict previous concerns regarding the safety of pioglitazone, and add to the controversy surrounding interpretation of rare adverse events associated with prescription drugs.
Original languageEnglish
Pages (from-to)655-656
Number of pages2
JournalNature Reviews Urology
Early online date29 Sep 2015
Publication statusPublished - 2015


  • Bladder cancer
  • Diabetes
  • Drug safety

Cite this